Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solution structure of iron(III)-anthracycline complexes.

M M Fiallo1, H Drechsel, A Garnier-Suillerot

  • 1Chimie Bioinorganique, LPBC, ESA 7033, Université Paris Nord, 74, rue Marcel Cachin, 93017 Bobigny Cedex, France. fiallo@smbh.univ-paris13.fr

Journal of Medicinal Chemistry
|July 30, 1999
PubMed
Summary

Iron(III) interacts with the anticancer drug idarubicin, forming two distinct complexes. These findings clarify the structure of iron-idarubicin complexes and may impact understanding of their biological effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uncapping the N-terminus of a ubiquitous His-tag peptide enhances its Cu<sup>2+</sup> binding affinity.

Dalton transactions (Cambridge, England : 2003)·2019
Same author

General aspects of metal toxicity.

Current medicinal chemistry·2014
Same author

Gonadoliberin (GnRH) and its copper complex (Cu-GnRH) enzymatic degradation in hypothalamic and pituitary tissue in vitro.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2012
Same author

Metal transport and homeostasis within the human body: toxicity associated with transport abnormalities.

Current medicinal chemistry·2012
Same author

Effects of laser radiation on Rhus vernicifera laccase, Type 2 Cu-depleted laccase, and stellacyanin.

Journal of inorganic biochemistry·2009
Same author

Interaction of Cis- and Trans-RuCl (2)(DMSO)(4) With Human Serum Albumin.

Metal-based drugs·2008

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Spectroscopy

Background:

  • Anthracyclines are a class of potent anticancer drugs.
  • Iron(III) is a biologically relevant metal ion that can interact with small molecules.
  • Understanding drug-metal interactions is crucial for drug efficacy and toxicity.

Purpose of the Study:

  • To investigate the complex formation between iron(III) and the anthracycline anticancer drug idarubicin.
  • To characterize the structure and stoichiometry of the resulting iron-idarubicin complexes.
  • To provide insights into the nature of these complexes for understanding their biological roles.

Main Methods:

  • Absorption spectroscopy
  • Circular Dichroism (CD) spectroscopy

Related Experiment Videos

  • Mössbauer spectroscopy
  • Electron Paramagnetic Resonance (EPR) spectroscopy

    • Main Results:

    • Two major iron(III)-idarubicin complexes (Complex I and Complex II) were identified.
    • Complex I features a 1:1 Fe(3+):idarubicin stoichiometry with iron binding at the {C(12)=O; C(11)-O(-)} site.
    • Complex II involves either a 2:1 Fe(3+):idarubicin ratio with iron at both {C(5)=O; C(6)-O(-)} and {C(12)=O; C(11)-O(-)} sites, or an oligomeric 1:1 structure.
    • The formation constants for the complexes were determined (beta(1) = 4.8 x 10(11) M(-1), beta(2) = 5.3 x 10(24) M(-2)).

    Conclusions:

    • The study elucidates the specific coordination sites and stoichiometry of iron(III)-idarubicin complexes.
    • Previous reports of 1:3 Fe(3+):anthracycline complexes may represent a mixture of the identified species and free ligand.
    • These findings contribute to understanding the biological activity of anthracycline-ferric complexes.